Roche Launches First Fully Automated Hepatitis D Virus Diagnostic Test, Addressing Critical Unmet Need
核心洞察
Roche introduces the cobas HDV test (搜索), the first high-throughput, fully automated assay for detecting and quantifying Hepatitis D (搜索) Virus RNA, now available in CE-mark accepting countries.
Hepatitis D (搜索) affects nearly 12 million people globally and is the most aggressive form of viral hepatitis, with super-infection leading to chronic disease in over 90% of cases.
The test runs on Roche's widely installed cobas 5800/6800/8800 platforms, enabling seamless laboratory integration and replacing inconsistent manual or lab-developed testing methods.
Roche announced on July 14, 2026, the introduction of the cobas HDV test (搜索), the first high-throughput, fully automated diagnostic assay for the detection and quantification of Hepatitis D (搜索) Virus (HDV) RNA. The test is now available in countries accepting the CE mark and runs on the company's cobas 5800, 6800, and 8800 systems, platforms already widely deployed in laboratories worldwide.
"This is an important advancement of our commitment to improving outcomes for people living with liver disease," said Matt Sause, CEO of Roche Diagnostics. "With the cobas HDV test (搜索), we are providing clinicians with a reliable tool to aid in the identification of infected individuals and to monitor their response to treatment."
The Burden of Hepatitis D (搜索)
Hepatitis D (搜索) affects an estimated 12 million people globally and is considered the most aggressive form of viral hepatitis, often leading to liver failure, cirrhosis, and liver cancer faster than other types. The virus is a unique satellite virus that can only infect individuals who already carry the Hepatitis B (搜索) virus (HBV). It can manifest as a co-infection—simultaneous infection with both viruses—or as a super-infection, where HDV infection occurs after chronic Hepatitis B is already established.
Co-infection may explain approximately one in five cases of liver disease, while super-infection is particularly dangerous, with over 90% of cases becoming chronic and accelerating toward liver damage. Symptoms can be severe and include jaundice, extreme fatigue, abdominal pain, and nausea. Because HDV requires HBV to replicate, vaccination against Hepatitis B (搜索) remains the most effective prevention strategy.
Closing a Critical Diagnostic Gap
Despite the severity of Hepatitis D (搜索), testing has historically been limited to manual methods or lab-developed tests that can vary in consistency. The cobas HDV test (搜索) addresses this gap by providing a standardized, automated solution that integrates seamlessly into existing laboratory workflows. By automating the testing process, laboratories can deliver accurate results faster and more efficiently, enabling clinicians to make timely treatment decisions.
The launch is particularly significant as new, specific treatments for HDV are becoming available in many markets. These emerging therapies require precise viral load monitoring to assess treatment response and guide patient care—a need that the cobas HDV test (搜索) is designed to fulfill.
The fully automated cobas 5800, 6800, and 8800 platforms on which the assay runs are already established in laboratories worldwide, allowing for rapid adoption without the need for additional infrastructure investment. Roche aims to expand access to critical HDV testing and strengthen the global response against one of the most aggressive forms of viral hepatitis.